A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas with Prior Exposure to Alkylating Agents
Study of Nivolumab (Study Drug) for Recurrent or Progressive IDH Mutant Gliomas
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAR6354
U.S. Govt. ID: NCT03557359
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test how well the study drug works in recurrent or isocitratedehydrogenase (IDH) mutant high grade gliomas. The study drug is called Nivolumab. Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow your own body's immune system to work against tumor cells. Nivolumab is not approved for use for gliomas in the United States.
This study is closed
Fabio Iwamoto, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with grade 3 or 4 gliomas? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator